Sign In
Buy MGTX
$9.39
+0.150 (+1.62%)
At Close: Jun 03, 2026
- MeiraGTx to receive $200 million in upfront cash consideration - MeiraGTx and Hologen will form a joint venture, Hologen Neuro AI Ltd, with an additional $230 million committed capital from Hologen
LONDON and NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the publication of re
MeiraGTx: 2 Possible Near-Term BLA Filings Could Ignite Shareholder Value
04:09pm, Wednesday, 22'nd Jan 2025
MeiraGTx Holdings plc is advancing AAV-AIPL1 for AIPL1-associated Leber congenital amaurosis 4, with a near-term BLA filing in the UK under Exceptional Circumstance possible. Bota-vec, developed with
MeiraGTx has recently received Rare Pediatric Disease Designation (RPDD) for four inherited retinal diseases (IRDs) reflecting the transformative therapeutic potential of the Company's proprietary tec
MeiraGTx Holdings: Behind The Recent Rally
02:18pm, Tuesday, 03'rd Dec 2024
MeiraGTx Holdings plc has rallied over 40% following promising Parkinson's disease data, with significant potential in its Riboswitch platform for gene expression control. The company's diverse pipeli
MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Tops Revenue Estimates
10:15am, Wednesday, 13'th Nov 2024
MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.74 per share a year ago.
MGTX Stock Up on Upbeat Efficacy Data From Parkinson's Disease Study
11:20am, Wednesday, 16'th Oct 2024
MeiraGTx stock rises 15% as gene therapy candidate betters sham treatment in Parkinson's disease patients.
MeiraGTx (MGTX) Surges 14.9%: Is This an Indication of Further Gains?
07:46am, Wednesday, 16'th Oct 2024
MeiraGTx (MGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
MeiraGTx: Positive PD Data Moves Needle Forward For Regulatory Meetings
01:32pm, Tuesday, 15'th Oct 2024
MeiraGTx Holdings plc's GAD gene therapy for Parkinson's Disease shows promising phase 1/2 results, with significant improvements in UPDRS Part 3 and PDQ-39 scores. The company plans to discuss phase
MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference
04:30pm, Wednesday, 09'th Oct 2024
Results indicate a potent and effective locally delivered AAV-BDNF gene therapy for the treatment of obesity caused by MC4R deficiency Results indicate a potent and effective locally delivered AAV-BDN
MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Lags Revenue Estimates
08:40am, Monday, 12'th Aug 2024
MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.53 per share a year ago.
- Positive data from the Phase 1 AQUAx study in radiation-induced xerostomia (RIX) presented at the American Academy of Oral Medicine 2024 annual meeting (AAOM) showed meaningful improvements in pati
MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi
07:03am, Monday, 12'th Aug 2024
LONDON and NEW YORK, Aug. 12, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicine company, today announced the pricing of an unde
5 Penny Stocks With 250% Upside in 1 Year According to Wall Street
08:49am, Tuesday, 30'th Jul 2024
Penny stocks represent an interesting investment opportunity.
MeiraGTx: A Very Attractive Longer-Term Play, With Potential Near-Term Catalysts
11:02am, Monday, 15'th Jul 2024
Bota-vec sale to JNJ/Janssen is complete – cash & future milestones from the deal should carry MeiraGTx through the next catalysts. The partnership with Sanofi strengthens the balance sheet and help
